GlassScriptPhysician profile
Vanessa C Pedrego
NPI 1467763755
$6,438.71
in general payments reported to CMS, 2019-2025
36 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $1,949 · 2023: $1,641 · 2024: $1,032 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,989 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,989.17 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,113.76 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $813.56 | 2021-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $588.52 | 2021-2023 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amgen INC. | $352.70 | 2022-2025 | Tepezza, Evenity, Repatha |
| Abbott Laboratories | $350.03 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.57 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $288.12 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $235.26 | 2021-2023 | Farxiga |
| Medtronic, INC. | $232.14 | 2022-2025 | Minimed 780g |
| Radius Health, INC. | $223.38 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $211.82 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $192.89 | 2022-2025 | Gvoke Hypopen |
| Insulet Corporation | $172.19 | 2021-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $138.60 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $115.34 | 2024-2025 | Korlym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $114.59 | 2021-2025 | |
| Mannkind Corporation | $114.33 | 2022-2023 | Afrezza |
| Ascendis Pharma Endocrinology INC | $82.68 | 2024-2025 | Yorvipath |
| Ionis Pharmaceuticals, INC. | $78.30 | 2025 | Tryngolza |
| Madrigal Pharmaceuticals | $76.33 | 2024 | Resmetirom |
| Amryt Pharma Holdings LTD | $70.86 | 2022-2023 | Mycapssa |
| Abbvie INC. | $70.21 | 2023-2025 | |
| Alvogen INC | $64.76 | 2022-2023 | Teriparatide |
| Merck Sharp & Dohme LLC | $63.82 | 2021-2022 | |
| Horizon Therapeutics Plc | $59.29 | 2021-2023 | Tepezza |
| Pfizer INC. | $46.21 | 2022-2025 | |
| Averitas Pharma INC. | $41.21 | 2025 | Qutenza |
| Lifescan, INC. | $29.65 | 2022 | |
| Chiesi USA, INC. | $29.41 | 2025 | Mycapssa |
| Rhythm Pharmaceuticals, INC. | $25.93 | 2025 | Imcivree |
| Bigfoot Biomedical INC | $24.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.63 | 2023 | Crysvita |
| Glaxosmithkline, LLC. | $19.27 | 2025 | Shingrix, Arexvy |
| Ibsa Pharma INC. | $15.97 | 2023 | Tirosint, Licart |
| Embecta Corp. | $13.84 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Kyowa Kirin, INC. | $12.75 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Pedrego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.